PDSB — PDS Biotechnology Share News
0.000.00%
Last trade - 00:00PDS Biotechnology Corp expected to post a loss of 28 cents a share - Earnings Preview
Brief: Pds Biotech Announces Presentation Of Rationale And Design Of First Recurrent Prostate Cancer Trial To Combine An Androgen Receptor Pathway Inhibitor With An Immunocytokine
Brief: PDS Biotech Announces Updated Results From Versatile-002 Phase 2 Clinical Trial Presented At Esmo 2024
PDS Biotechnology Corp reports results for the quarter ended in June - Earnings Summary
PDS Biotechnology Corp expected to post a loss of 34 cents a share - Earnings Preview
Brief: PDS Biotech Provides Data Update From Ongoing Versatile-002 Phase 2 Clinical Trial In Head And Neck Cancer
PDS Biotechnology Corp reports results for the quarter ended in March - Earnings Summary
Brief: PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints In First Line Recurrent/Metastatic HPV16-Positive Head, Neck Cancer
PDS Biotechnology Corp reports results for the quarter ended in December - Earnings Summary
PDS Biotechnology Corp expected to post a loss of 44 cents a share - Earnings Preview
Brief: PDS Biotechnology Corp Patent For Composition Of Matter And Use Of Infectimune Based Influenza Vaccines Granted In The United States
Brief: PDS Biotechnology Says On Nov. 21 Matthew Hill Submitted His Resignation, Effective December 1, 2023, As CFO
Brief: PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients
Brief: PDS Biotech Announces Preliminary Biomarker Study Results In Subset Of Advanced Hpv-Positive Head And Neck Cancer Patients
Brief: Pds Biotech Announces Interim Safety And Immune Response Data From Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate Pds0301 Combined With Docetaxel To Treat Metastatic Prostate Cancer
PDS Biotechnology Corp reports results for the quarter ended in June - Earnings Summary
Brief: Pds Biotech Reports Second Quarter 2023 Financial Results And Provides Business Update
Brief: Pds Biotech Announces Submission Of Phase 3 Protocol To FDA To Initiate Versatile-003 Trial
PDS Biotechnology Corp expected to post a loss of 35 cents a share - Earnings Preview